Nordion posted an increase in its second-quarter revenues for fiscal 2013 (end-April 30).
For the period, Nordion saw revenues of $56.1 million, up 12% from $50 million in the second quarter of fiscal 2012. However, the company's net income fell to $731,000 from $3.2 million in the same quarter a year ago.
For the six-month period, Nordion posted revenues of $109.7 million, up 7% from $103 million for the same period last year. Six-month net income fell to $462,000 from $2.3 million in 2012.
Second-quarter revenue from Nordion's TheraSphere brachytherapy product was $13.2 million, a 6% increase over $12.4 million in the same quarter of 2012. TheraSphere earnings were lower than anticipated because of increased expenses for sales and marketing and clinical trials, as well as higher general and administrative costs to support the product's growth.
Revenue in the company's Medical Isotopes business remained the same as last year, at $22.7 million. Reactor isotopes revenue was also flat, at $17.2 million, while cyclotron isotopes revenues were higher by 6%, mainly due to strontium-82 sales.
